Cara Therapeutics, Inc.

CARA

Canadian symbol:	CARA
US symbol:	CARA

Currency in USD

Valuation Measures

Market Cap (intraday) ⁵	955.78M
Enterprise Value ³	838.63M
Trailing P/E	N/A
Forward P/E ¹	-10.90
PEG Ratio (5 yr expected) ¹	N/A
Price/Sales (ttm)	34.75
Price/Book (mrq)	7.04
Enterprise Value/Revenue ³	30.49
Enterprise Value/EBITDA ⁶	-8.17

Trading Information

Stock Price History

Beta (5Y Monthly)	1.70
52-Week Change ³	18.61%
S&P500 52-Week Change ³	17.60%
52 Week High ³	21.64
52 Week Low ³	8.88
50-Day Moving Average ³	16.38
200-Day Moving Average ³	15.50

Share Statistics

Avg Vol (3 month) ³	437.93k
Avg Vol (10 day) ³	635.4k
Shares Outstanding ⁵	49.83M
Float	41.87M
% Held by Insiders ¹	10.47%
% Held by Institutions ¹	68.72%
Shares Short (Dec. 30, 2020) ⁴	3.84M
Short Ratio (Dec. 30, 2020) ⁴	9.2
Short % of Float (Dec. 30, 2020) ⁴	8.73%
Short % of Shares Outstanding (Dec. 30, 2020) ⁴	7.71%
Shares Short (prior month Nov. 29, 2020) ⁴	3.85M

Dividends & Splits

Forward Annual Dividend Rate ⁴	N/A
Forward Annual Dividend Yield ⁴	N/A
Trailing Annual Dividend Rate ³	N/A
Trailing Annual Dividend Yield ³	N/A
5 Year Average Dividend Yield ⁴	N/A
Payout Ratio ⁴	0.00%
Dividend Date ³	N/A
Ex-Dividend Date ⁴	N/A
Last Split Factor ²	1:2
Last Split Date ³	Jan. 15, 2014

Financial Highlights

Fiscal Year

Fiscal Year Ends	Dec. 30, 2019
Most Recent Quarter (mrq)	Sep. 29, 2020

Profitability

Profit Margin	0.00%
Operating Margin (ttm)	-374.04%

Management Effectiveness

Return on Assets (ttm)	-31.29%
Return on Equity (ttm)	-58.34%

Income Statement

Revenue (ttm)	27.5M
Revenue Per Share (ttm)	0.59
Quarterly Revenue Growth (yoy)	60.20%
Gross Profit (ttm)	-93.93M
EBITDA	-102.68M
Net Income Avi to Common (ttm)	-99.11M
Diluted EPS (ttm)	-2.12
Quarterly Earnings Growth (yoy)	N/A

Balance Sheet

Total Cash (mrq)	120.87M
Total Cash Per Share (mrq)	2.43
Total Debt (mrq)	3.72M
Total Debt/Equity (mrq)	2.91
Current Ratio (mrq)	8.00
Book Value Per Share (mrq)	2.73

Cash Flow Statement

Operating Cash Flow (ttm)	-118.74M
Levered Free Cash Flow (ttm)	-82.86M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.

Full screen

Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.

Company	News	Date
CARA Cara Therapeutics	2 months ago - seekingalpha Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2020 Results - Earnings Call Transcript Financials seekingalpha	2020-11-09 20:15 2 months ago
CARA Cara Therapeutics	2 months ago - prnewsleader Medical Marijuana Market Overview with Detailed Analysis, Competitive landscape, Future Growth and Forecast to 2020-2026 - PRnews Leader prnewsleader	2020-11-06 10:09 2 months ago
CARA Cara Therapeutics	3 months ago - eurowire Medical Marijuana Industry 2020: Global Market Size, Share, Trends, SWOT Analysis by Top Key Players, Demand and Forecast Report to 2026 - Eurowire eurowire	2020-10-27 07:30 3 months ago
CARA Cara Therapeutics	3 months ago - prnewsleader Medical Marijuana Market: Business Size\| Strategies\| Opportunities\| Future Trends\| Top Key Players\| Market Share and Global Analysis by Forecast \| Cara Therapeutics Inc., Cannabis Sativa Inc., CannaGrow Holdings - PRnews Leader prnewsleader	2020-10-19 09:54 3 months ago
CARA Cara Therapeutics	4 months ago - thedailychronicle Medical Marijuana Market is Thriving Worldwide 2020-2027 \| Leading Players – Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings, United Cannabis, Growblox Sciences, GreenGro Technologies, GW Pharmaceuticals, Lexaria Corp - The Daily Chronicle thedailychronicle	2020-09-14 03:33 4 months ago
CARA Cara Therapeutics	4 months ago - thedailychronicle Medical Marijuana Market Have High Growth But May Foresee Even Higher Value 2020-2026 \| Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings, United Cannabis, Growblox Sciences, GreenGro Technologies, GW Pharmaceuticals, Lexaria Corp, MMJ America etc. - The Daily Chronicle thedailychronicle	2020-09-13 12:36 4 months ago
CARA Cara Therapeutics	4 months ago - clarkscarlet Medical Marijuana Market is Booming Worldwide \| Lexaria Corp, United Cannabis Corporation, Cara Therapeutics Inc., GW Pharmaceuticals, plc, CannaGrow Holdings, Inc., Cannabis Sativa, Inc. - The Scarlet clarkscarlet	2020-09-03 10:42 4 months ago
CARA Cara Therapeutics	5 months ago - njmmanews Global Marijuana Market 2020 – Impact of COVID-19, Future Growth Analysis and Challenges \| Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings, United Cannabis, Growblox Sciences - NJ MMA News njmmanews	2020-08-18 18:49 5 months ago
CARA Cara Therapeutics	7 months ago - medicinsider Marijuana Market Giants Spending Is Going To Boom \| United Cannabis, Growblox Sciences, GreenGro Technologies - Medic Insider medicinsider	2020-06-20 01:12 7 months ago
CARA Cara Therapeutics	7 months ago - coleofduty Medical Marijuana Market 2020 Projections, Growth Opportunities, Trends, Companies Strategies and Forecast 2026 \| Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings - Cole of Duty coleofduty	2020-06-16 05:40 7 months ago
CARA Cara Therapeutics	8 months ago - coleofduty CANNABIS SEEDS MARKET MOVEMENTS BY 2026: HEALTHCARE INNVATION, INDUSTRY SHARE, GROWTH RATE, PRODUCT TYPES, REGIONAL TRENDS\| KEY DRIVERS-THE SCOTTS, CARA THERAPEUTICS, CANOPY GROWTH, MEDRELEAF, GW PHARMACEUTICALS, AURORA CANNABIS, APHRIA, CANNIMED ETC. - Cole of Duty coleofduty	2020-05-27 03:06 8 months ago
CARA Cara Therapeutics	8 months ago - seekingalpha Cara Therapeutics, Inc. 2020 Q1 - Results - Earnings Call Presentation Financials seekingalpha	2020-05-12 15:42 8 months ago
CARA Cara Therapeutics	8 months ago - marijuanastocks Cara Therapeutics, Inc. (CARA) to Present at the Virtual BofA Securities 2020 Health Care Conference marijuanastocks	2020-05-07 10:45 8 months ago
CARA Cara Therapeutics	9 months ago - coleofduty New Forecast Report on Medical Marijuana Market Development and Worldwide Share with Topmost Players Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings, United Cannabis – Cole Reports - Cole of Duty coleofduty	2020-05-01 08:12 9 months ago
CARA Cara Therapeutics	9 months ago - latestherald (COVID-19 UPDATE)Medical Marijuana Market Demand with Key Players Analysis Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings, United Ca…More - Latest Herald latestherald	2020-04-29 07:33 9 months ago
CARA Cara Therapeutics	9 months ago - amitnetserver New Report on Marijuana Market With the Forecast Period Considering to 2027: Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings – Aminet Market Reports - amitnetserver amitnetserver	2020-04-27 18:51 9 months ago
CARA Cara Therapeutics	9 months ago - bccourier Medical Marijuana Market Trends, Business Outlook 2020, Expanding Current Industry Status by Top Most Players: Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings - Bandera County Courier bccourier	2020-04-23 12:16 9 months ago
CARA Cara Therapeutics	9 months ago - coleofduty Medical Marijuana Market Set for Rapid Growth During 2020 – 2027: Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings – Cole Reports - Cole of Duty coleofduty	2020-04-22 11:57 9 months ago
CARA Cara Therapeutics	9 months ago - marijuanastocks Cara Therapeutics, Inc. (CARA) and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results marijuanastocks	2020-04-21 08:49 9 months ago
CARA Cara Therapeutics	9 months ago - sciencein Medical Marijuana Market to Witness Massive Growth by 2024 \| Key Companies Cara Therapeutics, Cannabis Sativa, CannaGrow Holdings,…More - Science In Me Science sciencein	2020-04-14 08:25 9 months ago
CARA Cara Therapeutics	10 months ago - marijuanastocks Cara Therapeutics, Inc. (CARA) Reports Clinical Updates marijuanastocks	2020-03-25 08:21 10 months ago
CARA Cara Therapeutics	10 months ago - bccourier Medical Marijuana Market Revenue and Share by Manufacturers forecast 2020 to 2025 Cannabis Sativa, Cara Therapeutics, Lexaria Corp, United Cannabis Corporation, CannaGrow Holdings Inc - Bandera County Courier bccourier	2020-03-16 01:09 10 months ago
CARA Cara Therapeutics	10 months ago - bccourier Know How Global Medical Marijuana Market is demanded globally by Cannabis Sativa, Cara Therapeutics, Lexaria Corp, United Cannabis Corporation - Bandera County Courier bccourier	2020-03-14 13:39 10 months ago
CARA Cara Therapeutics	10 months ago - timesplot Key Trends & Drivers of Marijuana Market One Needs to Know \| Governmental Policies, Economic Outlook with Strategic Decision Framework - Times Plot timesplot	2020-03-14 06:45 10 months ago
CARA Cara Therapeutics	11 months ago - seekingalpha Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q4 2019 Results - Earnings Call Transcript Financials seekingalpha	2020-02-27 21:10 11 months ago
CARA Cara Therapeutics	11 months ago - mjobserver 3 Cannabinoid Biotech Companies in ExodusPoint Capital Management's Portfolio mjobserver	2020-02-23 17:35 11 months ago
CARA Cara Therapeutics	11 months ago - marijuanastocks Cara Therapeutics, Inc. (CARA) to Announce Fourth Quarter and Full Year 2019 Financial Results Financials marijuanastocks	2020-02-21 09:10 11 months ago
CARA Cara Therapeutics	1 year ago - seekingalpha Trevi Therapeutics: A Promising Pruritus Player In 2020 seekingalpha	2020-01-15 13:15 1 year ago
CARA Cara Therapeutics	1 year ago - seekingalpha Cara Therapeutics Is An Undervalued Asset In 2020 Analyst seekingalpha	2020-01-13 12:15 1 year ago
CARA Cara Therapeutics	1 year ago - seekingalpha Cara Therapeutics: Recent Stock Price Plunge Was A Bit Exaggerated seekingalpha	2019-12-18 16:01 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Analyst finance	2019-12-09 02:09 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus finance	2019-12-03 07:31 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara therapeutics (cara) reports q3 loss, tops revenue estimates Financials Analyst finance	2019-11-19 08:37 1 year ago
CARA Cara Therapeutics	1 year ago - finance Here’s What Hedge Funds Think About Cara Therapeutics Inc (CARA) finance	2019-11-18 20:05 1 year ago
CARA Cara Therapeutics	1 year ago - finance Have Insiders Been Selling Cara Therapeutics, Inc. (NASDAQ:CARA) Shares? finance	2019-11-18 19:55 1 year ago
CARA Cara Therapeutics	1 year ago - finance Edited Transcript of CARA earnings conference call or presentation 5-Nov-19 9:30pm GMT Financials finance	2019-11-18 19:30 1 year ago
CARA Cara Therapeutics	1 year ago - finance Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock? finance	2019-11-18 04:07 1 year ago
CARA Cara Therapeutics	1 year ago - finance Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for Financials Analyst finance	2019-11-18 03:31 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics to Present at November Investor Conferences finance	2019-11-12 16:10 1 year ago
CARA Cara Therapeutics	1 year ago - marijuanastocks Cara Therapeutics, Inc. (CARA) Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results marijuanastocks	2019-11-11 14:12 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Reports Third Quarter 2019 Financial Results Financials finance	2019-11-06 00:33 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Announces Presentations at Kidney Week 2019 finance	2019-11-01 15:18 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019 Financials finance	2019-10-29 17:00 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus finance	2019-10-24 10:00 1 year ago
CARA Cara Therapeutics	1 year ago - finance How Much Of Cara Therapeutics, Inc. (NASDAQ:CARA) Do Institutions Own? finance	2019-09-19 10:30 1 year ago
CARA Cara Therapeutics	1 year ago - investing Venezuela's Armed Forces Bank slams Mastercard for halting card service investing	2019-09-04 20:55 1 year ago
CARA Cara Therapeutics	1 year ago - investing Venezuela opposition says Sullivan & Cromwell will lead debt restructuring investing	2019-09-03 14:25 1 year ago
CARA Cara Therapeutics	1 year ago - investing World Bank tribunal lowers ConocoPhillips award for Venezuela expropriation: document investing	2019-09-02 16:15 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Inc (CARA) Q2 2019 Earnings Call Transcript Financials finance	2019-08-21 18:30 1 year ago
CARA Cara Therapeutics	1 year ago - marijuanastocks Cara Therapeutics, Inc. (CARA) Enters into Commercial License Agreement marijuanastocks	2019-08-21 08:20 1 year ago
CARA Cara Therapeutics	1 year ago - finance Does Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Pay Reflect Performance? finance	2019-08-19 15:30 1 year ago
CARA Cara Therapeutics	1 year ago - investing Venezuela's congress to create committee for future debt renegotiation investing	2019-08-13 16:56 1 year ago
CARA Cara Therapeutics	1 year ago - investing Colgate warns Venezuelans not to buy fake imported toothpaste brands investing	2019-08-13 15:20 1 year ago
CARA Cara Therapeutics	1 year ago - finance Edited Transcript of CARA earnings conference call or presentation 7-Aug-19 8:30pm GMT Financials finance	2019-08-08 10:00 1 year ago
CARA Cara Therapeutics	1 year ago - seekingalpha Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2019 Results - Earnings Call Transcript Financials seekingalpha	2019-08-07 23:55 1 year ago
CARA Cara Therapeutics	1 year ago - finance Here's Why Cara Therapeutics Rose 11.3% in July finance	2019-08-05 15:00 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019 Financials finance	2019-07-31 16:30 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Floats New Stock Issue finance	2019-07-25 13:00 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Announces Proposed Offering of Common Stock finance	2019-07-24 16:25 1 year ago
CARA Cara Therapeutics	1 year ago - marijuanastocks Cara Therapeutics, Inc. (CARA) Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA™ marijuanastocks	2019-07-22 08:00 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Inc (CARA) CFO & Chief Strategy Officer Mani Mohindru Sold $935,775 of Shares finance	2019-07-20 18:30 1 year ago
CARA Cara Therapeutics	1 year ago - seekingalpha Cara Therapeutics: Wait For A Better Entry Opportunity seekingalpha	2019-07-16 11:25 1 year ago
CARA Cara Therapeutics	1 year ago - seekingalpha Cara Therapeutics And Korsuva: An Analgesic Opioid Peptide Targeting Cholestasis Pruritus seekingalpha	2019-07-15 15:45 1 year ago
CARA Cara Therapeutics	1 year ago - finance 3 Top Biotech Stocks to Buy for the 2nd Half of 2019 finance	2019-07-14 16:30 1 year ago
CARA Cara Therapeutics	1 year ago - finance Estimating The Fair Value Of Cara Therapeutics, Inc. (NASDAQ:CARA) finance	2019-07-13 10:00 1 year ago
CARA Cara Therapeutics	1 year ago - marijuanastocks Cara Therapeutics (CARA) Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ marijuanastocks	2019-07-11 08:55 1 year ago
CARA Cara Therapeutics	1 year ago - marijuanastocks Cara Therapeutics, Inc. (CARA) Announces Initiation of Phase 2 Trial of Oral KORSUVA™ marijuanastocks	2019-07-09 08:00 1 year ago
CARA Cara Therapeutics	1 year ago - investing Special Report: Why the military still stands by Venezuela's beleaguered president investing	2019-06-28 08:10 1 year ago
CARA Cara Therapeutics	1 year ago - investing Venezuela's Guaido asks Jamaica not to seize PDVSA refinery shares investing	2019-06-15 19:50 1 year ago
CARA Cara Therapeutics	1 year ago - seekingalpha Cara Therapeutics: Positive Phase III KALM-1 Results Make Me Feel Calm seekingalpha	2019-06-10 11:16 1 year ago
CARA Cara Therapeutics	1 year ago - investing Venezuela court orders trial for detained Citgo executives investing	2019-06-07 21:40 1 year ago
CARA Cara Therapeutics	1 year ago - seekingalpha Cara Therapeutics (CARA) Presents At Jefferies 2019 Healthcare Conference - Slideshow seekingalpha	2019-06-07 10:55 1 year ago
CARA Cara Therapeutics	1 year ago - investing Venezuela loses $1.4 billion of gold to banks for guarantees: sources investing	2019-06-06 15:30 1 year ago
CARA Cara Therapeutics	1 year ago - finance Is Cara Therapeutics a Buy Now? finance	2019-06-02 10:00 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference finance	2019-05-31 17:30 1 year ago
CARA Cara Therapeutics	1 year ago - marijuanastocks Cara Therapeutics, Inc. (CARA) to Present at the Jefferies 2019 Healthcare Conference marijuanastocks	2019-05-31 08:05 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Shares Up on Positive Phase III Data for Itchiness Drug finance	2019-05-30 15:00 1 year ago
CARA Cara Therapeutics	1 year ago - streetinsider Janney Ups Cara Therapeutics (CARA) Fair Value Price to $33 From $27 After Positive Trial Data, Keeps at Buy Analyst streetinsider	2019-05-30 14:55 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Rallies On Positive Clinical Readout For Pruritis Drug finance	2019-05-29 15:30 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Surges on Phase 3 Results for Itchiness Treatment finance	2019-05-29 15:30 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics stock up 12.6% after company announces positive Phase 3 data for itchiness treatment finance	2019-05-29 13:00 1 year ago
CARA Cara Therapeutics	1 year ago - finance Announcing: Cara Therapeutics (NASDAQ:CARA) Stock Increased An Energizing 193% In The Last Three Years finance	2019-05-29 12:00 1 year ago
CARA Cara Therapeutics	1 year ago - finance Why Cara Therapeutics Stock Is Soaring Today finance	2019-05-29 12:00 1 year ago
CARA Cara Therapeutics	1 year ago - marketwatch Cara Therapeutics surges 15.7% after company announces positive late-stage data for itchiness treatment marketwatch	2019-05-29 09:25 1 year ago
CARA Cara Therapeutics	1 year ago - finance 3 Top Small-Cap Stocks to Buy Right Now finance	2019-05-29 08:30 1 year ago
CARA Cara Therapeutics	1 year ago - marijuanastocks Cara Therapeutics, Inc. (CARA) Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ marijuanastocks	2019-05-29 07:55 1 year ago
CARA Cara Therapeutics	1 year ago - finance Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use finance	2019-05-23 12:30 1 year ago
CARA Cara Therapeutics	1 year ago - seekingalpha My Top 3 Companies Paving The Way For Medicinal Cannabis Research seekingalpha	2019-05-23 07:05 1 year ago
CARA Cara Therapeutics	1 year ago - investing Exclusive: Guaido says Washington should help Venezuela keep U.S. refiner Citgo investing	2019-05-22 17:50 1 year ago
CARA Cara Therapeutics	1 year ago - finance 3 Small-Cap Biotech Stocks You Can Buy Right Now finance	2019-05-17 19:30 1 year ago
CARA Cara Therapeutics	1 year ago - finance Did Hedge Funds Drop The Ball On Casa Therapeutics Inc (CARA) ? finance	2019-05-09 17:00 1 year ago
CARA Cara Therapeutics	1 year ago - finance Edited Transcript of CARA earnings conference call or presentation 7-May-19 8:30pm GMT Financials finance	2019-05-09 11:30 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Inc (CARA) Q1 2019 Earnings Call Transcript Financials finance	2019-05-08 15:30 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates Financials finance	2019-05-07 22:00 1 year ago
CARA Cara Therapeutics	1 year ago - seekingalpha Cara Therapeutics, Inc. (CARA) CEO Dr. Derek Chalmers on Q1 2019 Results - Earnings Call Transcript Financials seekingalpha	2019-05-07 21:35 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara: 1Q Earnings Snapshot Financials finance	2019-05-07 19:00 1 year ago
CARA Cara Therapeutics	1 year ago - seekingalpha Cara Therapeutics' Korsuva Is Likely To Fail In Itch, Stock To Trade To Cash ($2.50/Share, 87% Downside) Analyst seekingalpha	2019-05-06 16:00 1 year ago
CARA Cara Therapeutics	1 year ago - finance Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options finance	2019-05-06 14:30 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics to Announce First Quarter 2019 Financial Results on May 7, 2019 Financials finance	2019-04-30 21:00 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates Financials finance	2019-04-24 04:58 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Inc (CARA) Q4 2018 Earnings Conference Call Transcript Financials finance	2019-04-24 04:58 1 year ago
CARA Cara Therapeutics	1 year ago - finance These Four Marijuana Stocks Are Raising Eyebrows on Wednesday finance	2019-04-24 04:58 1 year ago
CARA Cara Therapeutics	1 year ago - finance Here's Why Cara Therapeutics Stock Rose as Much as 13.9% Today finance	2019-04-24 04:58 1 year ago
CARA Cara Therapeutics	1 year ago - finance Analysis: Positioning to Benefit within American Water Works, TripAdvisor, ACADIA Pharmaceuticals, Dril-Quip, Domtar, and Cara Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results Financials finance	2019-04-24 04:58 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference finance	2019-04-24 04:58 1 year ago
CARA Cara Therapeutics	1 year ago - finance Edited Transcript of CARA earnings conference call or presentation 12-Mar-19 8:30pm GMT Financials finance	2019-04-24 04:58 1 year ago
CARA Cara Therapeutics	1 year ago - finance 3 Top Small-Cap Biotech Stocks for Aggressive Investors finance	2019-04-24 04:58 1 year ago
CARA Cara Therapeutics	1 year ago - finance 3 Top Biotech Stocks to Buy in April finance	2019-04-24 04:58 1 year ago
CARA Cara Therapeutics	1 year ago - finance Why Cara Therapeutics Stock Jumped 15.1% in March finance	2019-04-24 04:58 1 year ago
CARA Cara Therapeutics	1 year ago - finance Cara Therapeutics Posts 2018 Revenue 15X over 2017, Questions, Catalysts, and Hurdles Every Marijuana Stock Investor Should be Considering Financials finance	2019-04-24 04:58 1 year ago
CARA Cara Therapeutics	1 year ago - finance Better Buy: GW Pharmaceuticals vs. Cara Therapeutics finance	2019-04-24 04:58 1 year ago

Currency in USD

Earnings Estimate	Current Qtr. (Dec 2020)	Next Qtr. (Mar 2021)	Current Year (2020)	Next Year (2021)
No. of Analysts	7	3	8	8
Avg. Estimate	0.36	-0.51	-1.22	-1.76
Low Estimate	-0.73	-0.63	-2.31	-2.51
High Estimate	1.63	-0.4	0.23	-0.87
Year Ago EPS	-0.61	-0.62	-2.49	-1.22

Revenue Estimate	Current Qtr. (Dec 2020)	Next Qtr. (Mar 2021)	Current Year (2020)	Next Year (2021)
No. of Analysts	7	3	8	8
Avg. Estimate	48.63M	3.38M	65.73M	28.16M
Low Estimate	4M	N/A	25.27M	N/A
High Estimate	112M	10.15M	134.99M	47.5M
Year Ago Sales	4.51M	4.76M	19.89M	65.73M
Sales Growth (year/est)	978.00%	-29.00%	230.50%	-57.20%

Earnings History	2019-12-30	2020-03-30	2020-06-29	2020-09-29
EPS Est.	-0.66	-0.62	-0.67	-0.6
EPS Actual	-0.61	-0.62	-0.54	-0.35
Difference	0.05	0	0.13	0.25
Surprise %	7.60%	0.00%	19.40%	41.70%

EPS Trend	Current Qtr. (Dec 2020)	Next Qtr. (Mar 2021)	Current Year (2020)	Next Year (2021)
Current Estimate	0.36	-0.51	-1.22	-1.76
7 Days Ago	0.36	-0.51	-1.22	-1.76
30 Days Ago	0.35	-0.56	-1.23	-1.78
60 Days Ago	0.35	-0.56	-1.23	-1.78
90 Days Ago	-0.59	-0.64	-2.35	-2.09

EPS Revisions	Current Qtr. (Dec 2020)	Next Qtr. (Mar 2021)	Current Year (2020)	Next Year (2021)
Up Last 7 Days	N/A	N/A	N/A	N/A
Up Last 30 Days	1	N/A	1	1
Down Last 7 Days	N/A	N/A	N/A	N/A
Down Last 30 Days	N/A	N/A	N/A	N/A

Growth Estimates	CARA	Industry	Sector(s)	S&P 500
Current Qtr.	159.00%	N/A	N/A	N/A
Next Qtr.	17.70%	N/A	N/A	N/A
Current Year	51.00%	N/A	N/A	N/A
Next Year	-44.30%	N/A	N/A	N/A
Next 5 Years (per annum)	N/A	N/A	N/A	N/A
Past 5 Years (per annum)	N/A	N/A	N/A	N/A

Insiders transactions are updated every hour.

Major Holders

Insider Roster

Insider Transactions

Major Holders

Currency in USD

Breakdown

10.47%	% of Shares Held by All Insider
68.72%	% of Shares Held by Institutions
76.76%	% of Float Held by Institutions
224	Number of Institutions Holding Shares

Top Institutional Holders

Holder	Shares	Date Reported	% Out	Value
Blackrock Inc.	3,694,949	Sep. 29, 2020	7.41%	47,018,226
Price (T.Rowe) Associates Inc	3,177,992	Sep. 29, 2020	6.38%	40,439,948
RHO Capital Partners Inc	2,799,058	Sep. 29, 2020	5.62%	35,618,013
Farallon Capital Management LLC	2,250,000	Sep. 29, 2020	4.52%	28,631,250
Vanguard Group, Inc. (The)	2,239,799	Sep. 29, 2020	4.49%	28,501,442
First Manhattan Company	2,124,421	Sep. 29, 2020	4.26%	27,033,257
Carmignac Gestion	1,905,680	Sep. 29, 2020	3.82%	24,249,778
Chescapmanager LLC	1,314,303	Sep. 29, 2020	2.64%	16,724,505
Bank of America Corporation	1,129,197	Sep. 29, 2020	2.27%	14,369,031
State Street Corporation	949,533	Sep. 29, 2020	1.91%	12,082,807

Top Mutual Fund Holders

Holder	Shares	Date Reported	% Out	Value
Vanguard Total Stock Market Index Fund	1,161,252	Sep. 29, 2020	2.33%	14,776,931
iShares Russell 2000 ETF	992,242	Dec. 30, 2020	1.99%	15,012,621
Price (T.Rowe) Health Sciences Fund	671,030	Sep. 29, 2020	1.35%	8,538,856
Vanguard Extended Market Index Fund	652,613	Sep. 29, 2020	1.31%	8,304,500
ETF Managers Tr-EFTMG Alternative Harvest ETF	647,082	Sep. 29, 2020	1.30%	8,234,118
Price (T.Rowe) New Horizons Fund	644,829	Sep. 29, 2020	1.29%	8,205,449
Price (T.Rowe) Small-Cap Value Fund	497,110	Sep. 29, 2020	1.00%	6,325,724
iShares NASDAQ Biotechnology ETF	436,635	Dec. 30, 2020	0.88%	6,606,287
Price (T.Rowe) Small Cap Stock Fund	414,707	Sep. 29, 2020	0.83%	5,277,146
iShares Russell 2000 Growth ETF	381,528	Dec. 30, 2020	0.77%	5,772,518

CARA Short Data (Canadian side):
https://shortdata.ca/stock/CARA/
IIROC Consolidated Short Position Report

CARA Short Interest (US side):
https://fintel.io/s/us/CARA/
US Short Volume
FINRA OTC Equity Short Interest

Coming Soon

Search SEDAR Filings

Company Name:

Document Type:

Start Date:

End Date:

Press Releases by Cara Therapeutics, Inc.

CalendarPress Release32 views2 min read

Cara Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Cara Therapeutics

STAMFORD, Conn., Jan. 06, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Exe... Read More...

Press Release112 views4 min read

Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus

Cara Therapeutics

First NDA submission for Company’s lead program, KORSUVA™ Injection –NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection –STAMFORD, Conn., Dec. 28, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical ... Read More...

Press Release133 views4 min read

SWK Holdings’ Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics

Cara Therapeutics

Second milestone payment related to the development of Oral KORSUVA™ follows initial $2.5 million milestone payment received in OctoberDALLAS, Dec. 24, 2020 -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its who... Read More...

Press Release104 views4 min read

Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Cara Therapeutics

- Topline data expected in first half of 2021 -STAMFORD, Conn., Dec. 02, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that it has... Read More...

FinancialsPress Release31 views0 min read

CARA Therapeutics, Inc. to Host Earnings Call

Cara Therapeutics

NEW YORK, NY / ACCESSWIRE / November 9, 2020 / CARA Therapeutics, Inc. (NASDAQ:CARA) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 9, 2020 at 4:30 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/event/presentatio... Read More...

FinancialsPress Release58 views36 min read

Cara Therapeutics Reports Third Quarter 2020 Financial Results

Cara Therapeutics

– Conference call today at 4:30 p.m. ET –STAMFORD, Conn., Nov. 09, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results a... Read More...

CalendarFinancialsPress Release102 views1 min read

Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020

Cara Therapeutics

STAMFORD, Conn., Nov. 02, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast... Read More...

Press Release61 views4 min read

SWK Holdings’ Subsidiary, Enteris BioPharma, Receives Milestone Payment from Cara Therapeutics

Cara Therapeutics

First of multiple anticipated milestone payments related to the development of Oral KORSUVA™DALLAS, Oct. 27, 2020 -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma, re... Read More...

Press Release76 views3 min read

Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020

Cara Therapeutics

- Results from global KALM-2 pivotal Phase 3 trial of KORSUVA™ Injection in hemodialysis patients with pruritus to be presented –- NDA submission for KORSUVA Injection on track for fourth quarter 2020 - STAMFORD, Conn., Oct. 21, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercia... Read More...

Press Release67 views7 min read

Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritus

Cara Therapeutics

Vifor Pharma secures commercial rights for IV Korsuva in non-Fresenius Medical Care dialysis clinics representing approx. 66% of the market, under a profit-sharing arrangement with CaraCara will receive a USD 100 million upfront payment and an equity investment of USD 50 millionIV Korsuva aims to address a significant unmet medical need f... Read More...

Press Release38 views3 min read

Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer

Cara Therapeutics

STAMFORD, Conn., Oct. 01, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the appointment of Thomas Reilly as Chief Financial Officer, effect... Read More...

FinancialsPress Release49 views40 min read

Cara Therapeutics Reports Second Quarter 2020 Financial Results

Cara Therapeutics

– Conference call today at 4:30 p.m. ET –STAMFORD, Conn., Aug. 10, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results a... Read More...

CalendarPress Release81 views1 min read

Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference

Cara Therapeutics

STAMFORD, Conn., Aug. 06, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Exe... Read More...

CalendarFinancialsPress Release39 views1 min read

Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020

Cara Therapeutics

STAMFORD, Conn., Aug. 03, 2020 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that the Company will host a conference call and live audio... Read More...

Press Release32 views3 min read

Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.

Cara Therapeutics

STAMFORD, Conn., June 30, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced the appointment of Susan Shiff, Ph.D., M.B.A., to its Boar... Read More...

Press Release43 views4 min read

Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Cara Therapeutics

- Patient enrollment increased approximately 28% to maintain >80% statistical power for primary endpoint and key registration endpoint of >4-point improvement responder analysis -- Full trial enrollment expected in fourth quarter of 2020 - STAMFORD, Conn., June 17, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical... Read More...

Press Release28 views1 min read

Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Cara Therapeutics

STAMFORD, Conn., May 27, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Exec... Read More...

FinancialsPress Release42 views27 min read

Cara Therapeutics Reports First Quarter 2020 Financial Results

Cara Therapeutics

STAMFORD, Conn., May 11, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced financial results and operational highlights for the first ... Read More...

Press Release46 views1 min read

Cara Therapeutics to Present at the Virtual BofA Securities 2020 Health Care Conference

Cara Therapeutics

STAMFORD, Conn., May 07, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Exec... Read More...

CalendarFinancialsPress Release29 views1 min read

Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020

Cara Therapeutics

STAMFORD, Conn., May 04, 2020 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast o... Read More...

Press Release34 views8 min read

VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus

Cara Therapeutics

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02) Statistically significant improvement in key secondary endpoint of proportion of patients with four point or greater reduction in mean worst itching intens... Read More...

Press Release45 views8 min read

Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma Announce Positive Results From Global KALM-2 Pivotal Phase 3 Trial of KORSUVATM Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics

Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean Worst Itching Intensity NRS score vs. placebo (p=0.02) -Statistically significant improvement in key secondary endpoint of proportion of patients with four point or greater reduction in mean worst itching inten... Read More...

Press Release29 views1 min read

Cara Therapeutics to Present at the Virtual 19th Annual Needham Healthcare Conference

Cara Therapeutics

STAMFORD, Conn., April 08, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Ex... Read More...

Press Release20 views4 min read

Cara Therapeutics Reports Clinical Updates

Cara Therapeutics

- On track to report topline data for KALM-2 Phase 3 global trial of KORSUVA™ Injection in second quarter – - On track to complete interim statistical analysis for ongoing Phase 2 trial of Oral KORSUVA in atopic dermatitis in second quarter - - Timeline to submit KORSUVA Injection New Drug Application to FDA in second h... Read More...

FinancialsPress Release3 views47 min read

Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Cara Therapeutics

STAMFORD, Conn., Feb. 27, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced financial results and operational highlights for the fourt... Read More...

CalendarFinancialsPress Release417 views1 min read

Cara Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020

Cara Therapeutics

STAMFORD, Conn., Feb. 20, 2020 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast ... Read More...

CalendarPress Release1 views1 min read

Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Cara Therapeutics

STAMFORD, Conn., Jan. 08, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 38th Annual J.P. Morgan Healthcare ... Read More...

Press Release1 views1 min read

Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan

Cara Therapeutics

STAMFORD, Conn., Dec. 06, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Compensation Committee of Cara’s Board of Directors has approved t... Read More...

Press Release1 views2 min read

Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

Cara Therapeutics

STAMFORD, Conn., Dec. 03, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 31st Annual Piper Jaffray Healthcar... Read More...

Press Release1 views6 min read

Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus

Cara Therapeutics

– Met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores with 1 mg tablet strength vs. placebo after 12-week treatment period (p=0.018) –– Oral KORSUVA™ well-tolerated after 12 weeks of treatment –– Conference call today at 8:30 a.m. ET –STAMFORD, Conn., Dec. 03, 2019 -- Cara Therapeutics,... Read More...

Press Release1 views1 min read

Cara Therapeutics to Present at November Investor Conferences

Cara Therapeutics

STAMFORD, Conn., Nov. 12, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced company management will present a corporate overview at two investor confer... Read More...

Press Release1 views22 min read

Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of Medicine

Cara Therapeutics

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)--sm Mt(0.8em)--sm" type="text" content="- Treatment with KORSUVA Injection resulted in statistically significant reduction in pruritus intensity and improvement in itch-related quality of life measures vs placebo for both primary and secondary endpoints -" data-... Read More...

FinancialsPress Release1 views19 min read

Cara Therapeutics Reports Third Quarter 2019 Financial Results

Cara Therapeutics

– Conference call today at 4:30 p.m. ET –STAMFORD, Conn., Nov. 05, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial results and operational ... Read More...

Press Release1 views3 min read

Cara Therapeutics Announces Presentations at Kidney Week 2019

Cara Therapeutics

Late-breaking oral presentation to highlight data from KALM-1 pivotal Phase 3 trial of KORSUVA™ Injection in hemodialysis patients with pruritusSTAMFORD, Conn., Nov. 01, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by sele... Read More...

FinancialsPress Release1 views1 min read

Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019

Cara Therapeutics

STAMFORD, Conn., Oct. 29, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Tues... Read More...

Press Release1 views4 min read

Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics

- Patient enrollment increased approximately 20% to maintain >90% statistical power - - Full trial enrollment expected in fourth quarter of 2019 -STAMFORD, Conn., Oct. 14, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treat... Read More...

Press Release1 views1 min read

Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

Cara Therapeutics

STAMFORD, Conn., Sept. 26, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 2019 Cantor Fitzgerald Global... Read More...

Press Release1 views3 min read

Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology

Cara Therapeutics

STAMFORD, Conn., Aug. 21, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has entered into a non-exclusive commerci... Read More...

Press Release1 views4 min read

Enteris BioPharma and Cara Therapeutics Enter into Licensing Agreement for Peptelligence® to Advance Development of Oral KORSUVA™

Cara Therapeutics

Deal Showcases the Potential of Peptelligence® as the "Gold Standard" Technology for Developing Oral Formulations of Peptide-Based DrugsOral KORSUVA™ is Currently the Subject of Three Separate Phase 2 Clinical Trials for Differing Indications of PruritisBOONTON, N.J., Aug. 21, 2019 -- Enteris BioPharma, Inc., a biotechnology company devel... Read More...

FinancialsPress Release1 views52 min read

Cara Therapeutics Reports Second Quarter 2019 Financial Results

Cara Therapeutics

– Conference call today at 4:30 p.m. ET –STAMFORD, Conn., Aug. 07, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced financial results and oper... Read More...

FinancialsPress Release1 views1 min read

Cara Therapeutics to Announce Second Quarter 2019 Financial Results on August 7, 2019

Cara Therapeutics

STAMFORD, Conn., July 31, 2019 -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Wedn... Read More...

Press Release1 views4 min read

Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Cara Therapeutics

STAMFORD, Conn., July 29, 2019 -- Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the closing of its underwritten public offering of 6,325,000... Read More...

Capital RaisePress Release1 views4 min read

Cara Therapeutics Announces Pricing of $126.5 Million Offering of Common Stock

Cara Therapeutics

STAMFORD, Conn., July 24, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the pricing of its underwritten public offering... Read More...

Press Release1 views4 min read

Cara Therapeutics Announces Proposed Offering of Common Stock

Cara Therapeutics

STAMFORD, Conn., July 24, 2019 -- Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has commenced an underwritten public offering of 5,0... Read More...

Press Release1 views4 min read

Cara Therapeutics Announces No Modifications in Trial Size for Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Pruritus after Completion of Interim Statistical Assessment

Cara Therapeutics

- Study now fully enrolled; topline data expected in 4Q 2019 -STAMFORD, Conn., July 22, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced t... Read More...

Press Release1 views4 min read

Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™ for Pruritus in Patients with Atopic Dermatitis

Cara Therapeutics

Oral KORSUVA is now the subject of three separate, ongoing Phase 2 clinical trialsBOONTON, N.J., July 11, 2019 -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics (CARA) on the successful initiation of its Phase 2 clinic... Read More...

Press Release1 views4 min read

Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis

Cara Therapeutics

STAMFORD, Conn., July 09, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefal... Read More...

Press Release1 views4 min read

Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)

Cara Therapeutics

STAMFORD, Conn., June 26, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefal... Read More...

Press Release1 views7 min read

Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus

Cara Therapeutics

- Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.000019) –- Statistically significant improvement in key secondary endpoint of proportion of patients with four point or greater reduction in mean worst itchi... Read More...

Press Release1 views1 min read

Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

Cara Therapeutics

STAMFORD, Conn., May 08, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the Bank of America Merrill Lynch 2019 H... Read More...

Cara Therapeutics, Inc.

Valuation Measures

Trading Information

Stock Price History

Share Statistics

Dividends & Splits

Financial Highlights

Fiscal Year

Profitability

Management Effectiveness

Income Statement

Balance Sheet

Cash Flow Statement

Cannabis Market and Business News

Major Holders

Breakdown

Top Institutional Holders

Top Mutual Fund Holders

Search SEDAR Filings

Press Releases by Cara Therapeutics, Inc.

Share this page

Make smarter investment strategies with in-depth news reports

Make smarter investment strategies
with in-depth news reports